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incidences of non-malignant relevant disease and irrelevant 
disease were measured, as well as the number of investiga-
tions required to determine relevance of findings. In TP53 
mutation carriers, 6 of 44 (13.6, 95% CI 5.2–27.4%) par-
ticipants were diagnosed with cancer during the study, all 
of which would be considered life threatening if untreated. 
Two were found to have two primary cancers. Two par-
ticipants with cancer had abnormalities on the MRI which 
were initially thought to be benign (a pericardial cyst and a 
uterine fibroid) but transpired to be sarcomas. No controls 
were diagnosed with cancer. Fifteen carriers (34.1, 95% CI 
20.5–49.9%) and seven controls (15.9, 95% CI 6.7–30.1%) 
underwent further investigations following the WB MRI 
for abnormalities that transpired to be benign (p = 0.049). 
The cancer detection rate in this group justifies a minimum 
baseline non-contrast WB MRI in germline TP53 mutation 
carriers. This should be adopted into national guidelines for 
management of adult TP53 mutation carriers in addition 
Abstract In the United Kingdom, current screening 
guidelines for TP53 germline mutation carriers solely rec-
ommends annual breast MRI, despite the wide spectrum 
of malignancies typically seen in this group. This study 
sought to investigate the role of one-off non-contrast whole-
body MRI (WB MRI) in the screening of asymptomatic 
TP53 mutation carriers. 44 TP53 mutation carriers and 
44 population controls were recruited. Scans were read by 
radiologists blinded to participant carrier status. The inci-
dence of malignancies diagnosed in TP53 mutation carri-
ers against general population controls was calculated. The 
Sibel Saya and Emma Killick—Joint first authorship.
Richard W. Whitehouse, Dow-Mu Koh, S. Aslam Sohaib, D. 
Gareth Evans and Rosalind A. Eeles—Joint last authorship.
Electronic supplementary material The online version of this 
article (doi:10.1007/s10689-017-9965-1) contains supplementary 
material, which is available to authorized users.
 * Rosalind A. Eeles 
 rosalind.eeles@icr.ac.uk
1 The Institute of Cancer Research, 15 Cotswold Road, Sutton 
SM2 5NG, London, UK
2 University Hospital Southampton NHS Foundation Trust, 
Southampton, UK
3 Royal Marsden NHS Foundation Trust, London, UK
4 Central Manchester University Hospitals NHS Foundation 
Trust, Manchester, UK
5 Cancer Unit, Queen Elizabeth Hospital, University Hospitals 
Birmingham, Birmingham, UK
6 Guys and St Thomas’ NHS Foundation Trust, London, UK
7 Great Ormond Street Hospital & UCL Institute for Women’s 
Health, London, UK
8 Oxford University Hospitals, Oxford, UK
9 University Hospitals Bristol NHS Foundation Trust, Bristol, 
UK
10 Sheffield Children’s NHS Foundation Trust, Sheffield, UK
11 University of Leicester, Leicester, UK
12 University of Cambridge, Cambridge, UK
13 Northwick Park Hospital, London, UK
14 Peter MacCallum Cancer Centre, Melbourne, Australia
15 St Georges Hospital, London, UK
16 Mater Hospital, Dublin, Ireland
 S. Saya et al.
1 3
to the current practice of contrast enhanced breast MRI 
imaging.
Keywords Whole body MRI · TP53 mutation carriers · 
Li Fraumeni syndrome · Controls · Screening
Introduction
Li-Fraumeni Syndrome (LFS) is a rare autosomal domi-
nant condition which predisposes individuals to numerous 
cancer types. The majority of families with LFS have been 
found to carry mutations in the TP53 gene [1–3]. Typical 
cancers in the Li-Fraumeni spectrum include soft tissue 
and bone sarcoma, breast, brain, adrenal cortical carcinoma 
and leukaemia [4], however an increased risk has also been 
found in many other cancer types [5, 6]. The cancers are 
typically young onset occurring 2 or 3 decades before the 
median in the general population [6], and individuals are 
predisposed to multiple malignancies [7]. The condition 
has a high penetrance, with a lifetime cancer risk of almost 
100% for females and 75% for males [8] and may have a 
birth incidence as high as 1 in 5000 [9].
In the United Kingdom, the National Institute for Health 
and Clinical Excellence (NICE) recommends annual breast 
MRI from age 20–49 years for female TP53 mutation car-
riers and to consider continuation of breast screening past 
age 50. Discussion of risk-reducing mastectomy is also 
recommended, however, no other surveillance is currently 
suggested in any guidelines. Screening across UK genetics 
centres varies and many employ an open-door policy for 
carriers experiencing symptoms.
Recent evidence suggests there may be a survival benefit 
with more intensive screening, including whole-body MRI 
(WB MRI) [10, 11]. Internationally, more intensive screen-
ing programmes are starting to become employed [12, 13] 
and, in particular, are being explored in the research setting 
[10, 14–16]. Several studies are employing WB MRI [14, 
17], others FDG-PET/CT [15, 16], and, most commonly, 
combinations of several physical examination, imaging and 
biochemical screening modalities [10, 14, 17]. Given the 
lack of radiation, WB MRI provides an attractive choice to 
screen this cohort of individuals with an increased suscep-
tibility to radiation-induced neoplasms [18, 19].
When considering a screening modality, the incidence of 
incidental findings is important in decision making whether 
to adopt the modality in guidelines. To our knowledge, no 
studies have employed a healthy control group to compare 
the incidence of malignancies and incidental findings to 
that found in the TP53 mutation carriers.
This pilot study aimed to assess the incidence of malig-
nancies diagnosed in asymptomatic TP53 mutation carriers 
using a non-contrast WB MRI against general population 
controls, as well as the incidences of non-malignant rele-
vant and irrelevant disease and the investigations required 
to determine relevance. It was hypothesised that more 
malignancies would be diagnosed in the TP53 mutation 
carrier cohort than in the controls and the ratio of relevant 
to non-relevant findings (relevant defined as needing defini-
tive treatment) would be higher in the TP53 mutation carri-
ers than controls.
Methods
Study subjects and data collection
From November 2012 through July 2016, TP53 mutation 
carriers were recruited through genetics services from 
across the United Kingdom and general population con-
trols through local advertisements. Carriers with a known 
low penetrance TP53 mutation (in the view of a geneticist) 
or a variant of unknown significance were excluded, as 
well as those with a malignancy diagnosed in the previous 
5 years [except non-melanomatous skin cancer or cervical 
carcinoma in situ (CIS)]. Population controls were sex and 
age (±5 years) matched to carriers and required to have no 
personal history of cancer (except non-melanomatous skin 
cancer or cervical CIS) and minimal family history of can-
cer (no first degree relative diagnosed before age 50 and 
only one first, second or third degree relative diagnosed at 
any age). Any person with current symptoms suggestive of 
malignancy was excluded.
An additional sub-study was included to examine the 
psychosocial impact of screening in this group of high-risk 
individuals, the results of which will be reported separately.
The research was approved by the Health Research 
Authority NRES Committee London—Brent (12/
LO/0781).
MRIs
MRI examinations were performed at The Royal Marsden 
NHS Foundation Trust or Central Manchester Univer-
sity Hospitals NHS Foundation Trust using a 1.5  T MRI 
machine (Siemens, Erlangen, Germany) from vertex to feet 
using conventional MR imaging sequences (T1-weighted, 
with or without fat suppressed T2-weighted/STIR 
sequences), as well as diffusion weighted images (Supple-
mentary Table 1). Slices were 0.8 cm thick and scans were 
not contrast enhanced. Comparisons of imaging techniques 
will be reported elsewhere.
Scans were read independently by two radiologists with 
at least 5 years’ experience, who were blinded to the muta-
tion status of the study participants. MRIs were divided 
into anatomical sections and each section scored 0 to 5 (0 
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normal findings, 1 definitely benign, 2 likely to be benign, 
3 equivocal, 4 likely to be malignant, 5 definitely malig-
nant). Initial recommendations for further investigations 
were made blinded to carrier status, however subsequent 
review and intervention was made with consideration of 
this factor. In a case of discrepancy a consensus reading 
was performed by the two study radiologists plus a radi-
ologist from the other centre. Ten percent of scans, selected 
randomly, were cross-read at both centres for quality assur-
ance. Lesions requiring investigation and incidental find-
ings were discussed in a cross centre video-linked multidis-
ciplinary team (MDT) meeting including PIs, radiologists 
and other study staff from both sites. All pathology was 
reviewed by expert pathologists in two tertiary cancer cen-
tres and at tumour-specific MDT meetings.
Sample size and statistical analysis
A total of 88 participants were recruited to the study, with 
44 carriers of TP53 mutations matched to 44 healthy pop-
ulation controls. This sample size was calculated for 80% 
power to detect a difference in cancer detection between the 
mutation carrier group and the control group assuming a 
20% cancer detection rate in the carrier group and 1% in 
the control group for a two-tailed analysis.
The efficacy of WB MRI as a screening tool was evalu-
ated by diagnosis of early stage malignancy in asympto-
matic individuals, with respect to the number of further 
investigations required and false positives. Incidence of 
malignancies with 95% confidence intervals was calcu-
lated in both carrier and control groups and any difference 
between groups was compared using Chi square or Fisher’s 
exact test as appropriate at a 5% significance level. The 
incidence of and proportion of the cohort with relevant and 
non-relevant MRI findings is reported with 95% confidence 
intervals. Of those who were recalled, additional investiga-
tions with non-malignant results were reported with 95% 
confidence intervals and any difference between groups 
assessed using Mann–Whitney test. All statistical tests 
were two-sided and analysis was performed using STATA 
[20].
Results
Patient characteristics
Forty-four TP53 mutation carriers from 37 families and 
44 matched healthy population controls were recruited 
(Table  1). Nine of the 27 female TP53 carriers had had 
risk-reducing surgery of some kind, or mastectomies for 
previous breast cancer.
Cancer diagnoses and treatments
In TP53 mutation carriers, six of 44 (13.6, 95% CI 
5.2–27.4%) participants were diagnosed with cancer during 
the study (Table 2). Only four (9.1, 95% CI 2.5–21.7%) of 
these were a direct result of the study WB MRI, however 
two participants had two simultaneous primary tumours 
diagnosed. There was no diagnosis of cancer in the control 
group. Analysis showed no statistically significant differ-
ence in number of TP53 mutation carriers diagnosed with 
Table 1  Characteristics of the cases and controls with previous 
malignant tumours
*Four bilateral breast cancers; two phylloides tumours
Carriers Controls
n 44 44
Age, median (range) 38 (19–58) 38 (22–59)
Female, n (%) 27 (61%) 27 (61%)
Male, n (%) 17 (39%) 17 (39%)
Previous diagnosis of cancer, n (%) 18 (41%) 0
 Breast 11*
 Sarcoma 6
 Melanoma 2
 Ovarian 1
 Wilms tumour 1
 Cervical 1
 Adrenocortical carcinoma 1
 Teratoma 1
History of multiple cancers, n (%) 6 (13.6%) 0
Table 2  WB MRI outcomes WB MRI outcome Overall Carriers Controls
Further investiga-
tions triggered by 
WB MRI
Cancer detected (true positives) 4 4 0
Eventual benign outcome (false positives) 16 9 7
Requiring continued surveillance/Treatment 
(non-malignant)
3 3 0
No further investi-
gations triggered 
by WB MRI
NAD (true negatives) 63 26 37
Subsequent cancer diagnosis (false negatives) 2 2 0
Total 88 44 44
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malignancy compared to controls (p = 0.116), however 
the study was powered at a higher cancer detection rate in 
TP53 mutation carriers. Table 3.
All four individuals with screen detected cancers were 
women who were asymptomatic and all were treated with 
curative intent.
The first woman had a low grade astrocytoma in the 
right inferior temporal gyrus and underwent a R0 resec-
tion with full post-operative recovery 2 years after surgery. 
Upon questioning after her diagnosis she retrospectively 
reported episodes of déjà vu but no other symptoms and 
had never had a cancer diagnosis previously.
The second woman was diagnosed with a myxosar-
coma in the abdominal wall (Trojani grade 2). The size was 
46 × 37 mm and all margins were free indicating complete 
surgical excision. She did not require additional chemother-
apy or radiotherapy. This patient had a previous cancer his-
tory of ovarian teratoma at age 4, phylloides tumour of the 
breast aged 41 and DCIS breast cancer at 42 and a fibrosar-
coma of the left thigh at 42.
The third woman was 45  years of age and reported 
irregular menstrual cycle on enrolment. She had no history 
of cancer and was found to have a 10.6 × 8.6  cm mass of 
the right kidney on WB MRI. The differential diagnosis 
included an oncocytoma or renal cell carcinoma. Addition-
ally, two uterine fibroids and an ovarian cyst were detected. 
Following renal CT and pelvic MRI, she underwent a right 
nephrectomy and given her carrier status and age, simul-
taneous total abdominal hysterectomy, right salpingectomy 
(right ovary previously excised) and left salpingo-oopho-
rectomy. A 110  mm chromophobe renal cell carcinoma 
(Fuhrman grade 3) confined to the kidney with no lympho-
vascular invasion was detected, plus an incidental benign 
renal angiomyolipoma measuring 15  mm. In the resected 
uterus, 2 fibroids were present; the larger (65  mm) was 
found to be a leiomyosarcoma confined to the myometrium 
with no evidence of vascular invasion, and the smaller 
(25 mm) fibroid was a benign leiomyoma. The left ovary 
contained a benign cyst and interestingly both fallopian 
tube fimbrial ends were noted to contain scattered atypical 
epithelial cells with severe cytological atypia, thought to be 
more consistent with a tubal intra-epithelial lesion in transi-
tion rather than a definite serous intra-epithelial carcinoma. 
Both the uterine and renal tumour resections were R0 and 
no further treatment was required.
The fourth participant had previously had a rhabdo-
myosarcoma at 6  months of age. During the study, three 
tumours were detected, of which the first two (in the liver 
and right kidney) were detected on the initial WB MRI. 
Subsequent dedicated liver and renal MRIs were inconclu-
sive but were strongly suspicious of malignancy. Resection 
of the lesions revealed epithelioid angiomyolipomas in both 
organs, with suspiciously high mitotic incidence, however 
their malignant potential was unclear, as was the synchro-
nicity of the tumours. Given the rarity of angiomyolipo-
mas, tuberous sclerosis was subsequently ruled out. While 
on follow up for these initial tumours, a new left sacroiliac 
lesion was detected 19  months after the initial WB MRI. 
This was initially monitored then biopsied, diagnosing a 
high-grade chondroblastic osteosarcoma. The patient has 
completed methotrexate, doxorubicin and cisplatin (MAP) 
chemotherapy; surgery has been advised but the patient is 
pursuing proton beam therapy in the USA.
An additional patient had a pericardial cyst (seen on 
WB MRI) that was initially reported as likely benign but 
became symptomatic and non-study dedicated MRI and 
biopsy revealed a mediastinal sarcoma. The sixth was diag-
nosed with B-cell acute lymphocytic leukaemia 9 months 
after his whole-body MRI. This patient’s WB MRI was 
negative and he only reported some upper abdominal dis-
comfort when questioned on enrolment in the study.
Non-malignant findings from WB MRI
Outcomes of findings from the WB MRI are detailed in 
Table  2 with further details of all investigations in Sup-
plementary Table  2. Fifteen carriers (34.1%, 95% CI 
20.5–49.9%) and 7 controls (15.9%, 95% CI 6.7–30.1%) 
underwent further investigations after their WB MRI that 
did not result in a diagnosis of cancer (Table  5). There 
was a marginally significant difference between the groups 
(p = 0.049). Six carriers and one control had more than 
one follow-up investigation (Table 4). Of those who were 
recalled, TP53 mutation carriers on average had 2.33 (95% 
CI 1.17–3.50) additional investigations with non-malignant 
results and controls 1.14 (95% CI 0.79 to 1.49). There was 
no significant difference between groups (p = 0.101).
There was one case in a TP53 mutation carrier of a 
non-malignant incidental finding that needed intervention 
(triggering a rheumatology referral) and additionally three 
lesions in two TP53 mutation carriers are requiring contin-
ued surveillance given their genetic status (3 of 44, 6.8%; 
95% CI 1.4–18.7%).
Eight investigations with non-malignant results (four 
CTs, two PET-CT scans and one X-ray) were carried out 
in five carriers using imaging techniques that exposed the 
participant to radiation (Table  5). However the majority 
of investigations conferred no exposure: most commonly, 
MRI imaging was used (13 scans in carriers and two in 
controls, either repeat scanning to monitor growth of the 
lesion, addition of contrast or more detailed imaging), then 
ultrasound (eight scans in carriers and six in controls). 
Two invasive procedures that did not result in a diagno-
sis of cancer were undertaken in carriers in the study: a 
biopsy of a suspicious pelvic bone lesion and the simulta-
neous salpingo-oophorectomy (for likely ovarian cyst) with 
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nephrectomy and hysterectomy in the case of the chromo-
phobe renal cell cancer.
Discussion
The SIGNIFY baseline WB MRI study demonstrates an 
overall cancer detection rate of 9.1% in prevalent WB MRI 
scans in TP53 mutation carriers with no cancers identified 
in controls (p = 0.116). The peak annual incidence rate for 
malignancy in TP53 mutation carriers is around 3% [21] 
therefore the prevalence in study of 9.1% suggests there 
is significant lead time in the cancers detected which indi-
cates that such screening is likely to be effective in LFS. 
This would be further demonstrated by a low detection 
rate at a subsequent annual incident screens which remains 
to be proven. Similar findings of a high prevalent detec-
tion rate was found in the MARIBS study [22, 23] (which 
included TP53 mutation carriers) with 2.7% of 632 women 
detected with breast cancer at prevalent screen dropping 
to 1.2% at the first incident round. This has translated into 
a significant survival benefit in women undergoing breast 
MRI screening [22].
The detection rate at prevalent screen could have been 
higher at 11.3% if further dedicated MRI had been per-
formed as part of the study to detect the mediastinal sar-
coma that had presented with a pericardial fluid collection 
that appeared to be a benign cyst. Additionally, the seem-
ingly benign appearance of the uterine leiomyosarcoma 
also argues for a lower threshold for suspicion in this high 
risk cohort. Although, further investigation of these appar-
ent benign features would lead to a higher rate of subse-
quent radiological investigation, this may translate into 
higher tumour survival rates. Complete resection of a brain 
astrocytoma, abdominal wall sarcoma and liver, kidney 
and uterine tumours may not have been possible without 
presymptomatic MRI detection in the current study. Sarco-
mas and brain malignancy in TP53 mutation carriers have 
poor overall survival rates and without curative surgery 
patients gain little benefit from chemotherapy or radiother-
apy [24–26]. Indeed the avoidance of radiotherapy through 
complete surgical excision may well prevent future radia-
tion induced malignancy that appears to be very high in 
TP53 mutation carriers [18]. It is likely that annual WB 
MRI [10, 11] will be required as sarcomas in TP53 muta-
tion carriers are often high grade and one patient already 
developed an osteosarcoma 19 months after a true negative 
prevalent scan.
Thus far if the missed mediastinal sarcoma and leu-
kaemia are included, two symptomatic malignancies have 
developed in the 12-months post prevalent MRI. The leu-
kaemia would not have been expected to be detected and 
further additional blood and other tests need to be consid-
ered in TP53 mutation carriers as occurs in the Toronto 
protocol [10, 11]. In particular we do not believe that WB 
MRI will replace dedicated breast MRI which requires a 
breast coil and gadolinium injection for the highest sensi-
tivity [23]. This indicates that both screening measures will 
be needed in the management of TP53 mutation carriers. 
It is not yet known how often such scans should be under-
taken; at present breast MRI is performed annually from 20 
to 50 years, but further studies are needed to assess if WB 
MRI needs to be repeated annually concurrently.
There was a high rate of identification of incidental find-
ings at WB MRI. More than twice as many TP53 muta-
tion carriers required further investigation for incidental 
findings, resulting in a marginally significant difference 
between the groups (p = 0.049). Carriers who were recalled 
also had a higher number of repeat scans compared to con-
trols, however this difference did not reach significance 
(p = 0.110). We are awaiting the psychological outcomes of 
these in a study related protocol, but this high rate of inves-
tigation including eight TP53 mutation carriers versus zero 
controls requiring modalities involving radiation for further 
Table 4  Multiple Investigations after WB MRI with Non-Malignant 
Results
a Including 2 TP53 mutation carriers diagnosed with cancer and addi-
tional incidental findings requiring investigations
Total 
number 
additional 
investiga-
tions
1 inves-
tigation 
(n)
2 inves-
tigations 
(n)
3 inves-
tigations 
(n)
≥ 4 
investi-
gations 
(n)
Carriers 
(n = 15)
35 9a 1 1 4
Controls 
(n = 7)
8 6 1 0 0
Table 5  Number and type of follow up investigations with Non-
Malignant Results
a Including investigations for non-malignant findings in three TP53 
mutation carriers with eventual cancer diagnoses
b Three scans are pending results (two TP53 mutation carriers and one 
control)
Overall 
(n = 22)
Carriers 
(n = 15)a
Con-
trols 
(n = 7)
Total investigations 43 35 8
Radiation positive imaging 8 8 0
Other imaging 29b 21a 8
Biopsy/removal before defini-
tive diagnosis
2 2a 0
Other investigations 4 4a 0
Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation…
1 3
investigation is of concern. Nonetheless the higher rate of 
these findings may presage future malignancy risk as evi-
denced by the finding of apparent benign cystic lesions in 
the bone and pericardium that were found to be tumour 
related.
This study only considered mutation carriers with muta-
tions previously known to be of high penetrance and it is 
possible that the balance of incidental findings and relevant 
tumour detection may not be the same in those with low 
penetrance mutations, such as the Brazilian founder muta-
tion [27]. The increase in use of gene panels in families 
or individuals with cancer without a history of classical 
LFS or LFL syndrome will identify more individuals with 
germline TP53 mutations where the penetrance may be 
lower and the role of WB MRI in such individuals is still 
uncertain.
LFS leads to tumours in both children and adults, how-
ever it was not possible to examine the role of screening 
children in the present study as the Ethics Committee 
passed the protocol to be undertaken in adults only. Fur-
thermore, studies from Toronto have published the use of 
screening in the paediatric age group [10, 11].
The present study has some limitations. The study size 
was not sufficient to detect significant differences in tumour 
rates between cases and controls, but the trend of the data 
are compelling. Nonetheless the blinding of radiologists to 
cases and controls, the first time we are aware this has been 
done, is an obvious strength. In particular, the imaging of 
controls has demonstrated the incidental finding incidence 
in a small general population cohort. It is interesting that 
the rate of recall for further scans was higher in mutation 
carriers and there are animal data that suggest that mutation 
carriers may have dysmorphic features [28, 29]. It would 
be ideal to undertake an international meta-analysis of WB 
MRI data in TP53 mutation carriers.
The malignancy prevalence of 13.6% in this study, 
detection rate on initial MRI of 9.1% and two cases of 
simultaneous primary cancers in two participants all argue 
for the adoption of at least a baseline whole body MRI scan 
in the screening of TP53 mutation carriers. Given the rarity 
of this condition and the relative ease of delivery of MRI 
without contrast, this additional screen warrants further 
research prior to incorporation into national guidelines for 
management of adult TP53 mutation carriers in addition 
to the current practice of gadolinium enhanced breast MRI 
imaging.
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